医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

LONDON & BOSTON & TOKYO

Innovation will continue to drive the pharma and biotech sectors in 2015 as forecasts point to another prosperous year according to EP Vantage’s latest report, “Pharma & Biotech 2015 Preview.” EP Vantage is the editorial arm of market intelligence firm Evaluate Ltd.

Key findings:

• A dozen products due to be launched next year are forecast to achieve blockbuster sales by 2020
• Drugs treating high cholesterol and heart failure will dominate the field with a combined 2020 sales forecast of $8 billion
• Sovaldi and its combination product Harvoni will take the number one worldwide seller spot with forecasted sales of $15.3 billion in 2015
• Patent expiries will have minimal impact on the top line as 2015 sales will grow close to four times that of patent losses
• Financing climate appears friendly and deals will continue at a steady pace but M&A activity unlikely to match the frenzy of 2014

“Cancer will also have a huge year as the promise of immuno-oncology therapies are further tested,” said Amy Brown, EP Vantage reporter and report author. “But with payers looking to restrain drug prices, marketed products may face heightened commercialization risks. Nonetheless, if 2015 lives up to today’s heady expectations, it will be a remarkable year that the sector will long remember.”

The “Pharma & Biotech 2015 Preview” report based on market intelligence and consensus forecasts from EvaluatePharma® can be downloaded at http://www.evaluategroup.com/PharmaBiotech2015Preview.

About Evaluate Ltd.

Evaluate is the trusted source for life science market intelligence and analysis with exclusive consensus forecasts to 2020. Our services include EvaluatePharma, EvaluateClinical Trials and EvaluateMedTech. Our award-winning editorial team, EP Vantage, leverages our strategic analysis to cut through the noise, giving you daily opinion and insights. The Evaluate services enable the life science community to make sound business decisions about value and opportunity. For more information please visit www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @epclinicaltrial, @epvantage.